stockrow
Monday 9 November 2026
Export ETRA’s income statement to Excel — free account
Electra Therapeutics Inc.
ETRA
8.50
0.70
+8.97%
Follow ETRA
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | |||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT margin, % | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Net income | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Per share, $ | |||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | — | — | — | — | |||||
| Earnings | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Cash flow | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Capex | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Book value | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Shares, m | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Valuation, × | |||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Cash, $m | |||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | — | — | — | — | |||||
| Capex | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Balance, $m | |||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | — | — | — | |||||
| Net debt | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Returns, % | |||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | — | — | — | — | |||||
| ROIC | — | — | — | — | — | — | — | — | — | — | — | ||||||
| ROE | — | — | — | — | — | — | — | — | — | — | — | ||||||
| People | |||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | — | 46 | — | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | — | 0.00 | — | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 23 Sep 2026
Electra Therapeutics Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| INDP Indaptus Therapeutics, Inc. | $509.9M | — (loss-making) | — | — | n/m | +52.03% (above 0%: growing) | 0.00% | 0.00% | Compare |
| DMAC DiaMedica Therapeutics, Inc. | $504.7M | — (loss-making) | — (loss-making) | — | n/m | −6.75% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| RGNX REGENXBIO Inc. | $503.9M | — (loss-making) | — (loss-making) | −69.19% (below 0%: shrinking) | n/m | +168.05% (above 0%: growing) | 87.55% | (387.84%) | Compare |
| CBIO Crescent Biopharma, Inc. | $502.9M | — (loss-making) | — (loss-making) | +1,038,900.00% (above 0%: growing) | n/m | −7.04% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| ETRA Electra Therapeutics Inc. | $489.6M | — | — | — | — | — | — | — | |
| MDXG MiMedx Group, Inc | $483.0M | — (loss-making) | — (loss-making) | −45.23% (below 0%: shrinking) | n/m | −87.21% (below 0%: shrinking) | 79.80% | (18.79%) | Compare |
| MNPR Monopar Therapeutics Inc. | $479.4M | — (loss-making) | — | — | n/m | −201.41% (below 0%: shrinking) | — | 0.00% | Compare |
| CTMX CytomX Therapeutics, Inc. | $477.4M | — (loss-making) | — (loss-making) | −71.69% (below 0%: shrinking) | n/m | +204.14% (above 0%: growing) | 100.00% | (1,392.30%) | Compare |
| STTK Shattuck Labs, Inc. | $470.5M | — (loss-making) | — (loss-making) | −10.31% (below 0%: shrinking) | n/m | +1.01% (above 0%: growing) | 100.00% | 0.00% | Compare |
| Median of peers | $493.0M | — | — | −45.23% | — | −2.87% | 87.55% | 0.00% |